Question special
Moderator

Hello everyone, I’m excited to be helping to facilitate the discussion this week! Thanks to the authors and experts for participating, and congratulations on this breakthrough study.

This is a phase II, open label, single arm trial, with 50 patients enrolled who have metastatic castration-resistant prostate cancer. Some of the prior treatments include docetaxel, cabazitaxel, abiraterone or enzalutamide. 16 of the 49 evaluable patents responded to this treatment—a response rate of 32.7%. 87.5% of those who responded were found to have DNA repair defects detected by NGS and digital PCR from tumor biopsies.

To start off broadly, please elaborate on the breakthrough elements in this study. Do they lie in the further expansion of the applications of PARP inhibitors--used currently for DNA repair defective ovarian cancer--to now prostate cancers? Do they lie in the use of NGS for the detection of genetic markers and for molecular stratification of prostate cancers?